22 November 2022>: Original Paper
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipients with Hepatocellular Carcinoma
Gonzalo Sapisochin 1ADE** , Wei Chen Lee 2ABCDE , Dong Jin Joo 3ABD , Jae-Won Joh 4ABE , Koichiro Hata 56BCDE , Arvinder Singh Soin 7ACDE , Uday Kiran Veldandi 8ABCDEF , Shuhei Kaneko 9ACDE , Matthias Meier 10ACDEG , Denise Leclair 11DE , Gangadhar Sunkara 11CDEF , Long Bin Jeng 12AB**DOI: 10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
Figure 3 Kaplan-Meier plot for proportion of patients (ITT population) free from HCC recurrence (A) and free from HCC recurrence or death (B). EVR+rTAC – everolimus plus reduced tacrolimus; HCC – hepatocellular carcinoma; ITT – intent-to-treat; sTAC – standard tacrolimus. Created using SAS version 9.4.